These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 36341333)

  • 1. Immunotherapeutic progress and application of bispecific antibody in cancer.
    Kang J; Sun T; Zhang Y
    Front Immunol; 2022; 13():1020003. PubMed ID: 36341333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
    Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
    Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific Antibodies: From Research to Clinical Application.
    Ma J; Mo Y; Tang M; Shen J; Qi Y; Zhao W; Huang Y; Xu Y; Qian C
    Front Immunol; 2021; 12():626616. PubMed ID: 34025638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.
    Li H; Er Saw P; Song E
    Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
    Zhang T; Lin Y; Gao Q
    Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
    Wei J; Yang Y; Wang G; Liu M
    Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
    Long M; Mims AS; Li Z
    Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
    Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
    Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy.
    Chen S; Li L; Zhang F; Wang Y; Hu Y; Zhao L
    J Immunol Res; 2019; 2019():4516041. PubMed ID: 30886871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
    Hong Y; Nam SM; Moon A
    Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The present and future of bispecific antibodies for cancer therapy.
    Klein C; Brinkmann U; Reichert JM; Kontermann RE
    Nat Rev Drug Discov; 2024 Apr; 23(4):301-319. PubMed ID: 38448606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
    Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
    Front Immunol; 2020; 11():762. PubMed ID: 32457743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibodies: design, therapy, perspectives.
    Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
    Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunities and challenges of bi-specific antibodies.
    Segués A; Huang S; Sijts A; Berraondo P; Zaiss DM
    Int Rev Cell Mol Biol; 2022; 369():45-70. PubMed ID: 35777864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology drives the discovery of bispecific antibodies as innovative therapeutics.
    Nie S; Wang Z; Moscoso-Castro M; D'Souza P; Lei C; Xu J; Gu J
    Antib Ther; 2020 Jan; 3(1):18-62. PubMed ID: 33928225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent advances in the development of bispecific antibodies].
    Ye J; Meng S; Zhu X
    Sheng Wu Gong Cheng Xue Bao; 2020 Jan; 36(1):33-43. PubMed ID: 32072779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy.
    Acheampong DO; Adokoh CK; Ampomah P; Agyirifor DS; Dadzie I; Ackah FA; Asiamah EA
    Protein Pept Lett; 2017; 24(5):456-465. PubMed ID: 28117014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.
    Guo X; Wu Y; Xue Y; Xie N; Shen G
    Front Immunol; 2023; 14():1291836. PubMed ID: 38106416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis.
    Nejadghaderi SA; Balibegloo M; Noori M; Fayyaz F; Saghazadeh A; Rezaei N
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):307-318. PubMed ID: 36856069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.
    Zhang B; Li W; Fan D; Tian W; Zhou J; Ji Z; Song Y
    Immunology; 2022 Sep; 167(1):15-27. PubMed ID: 35575882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.